Geron Corporation Sets 2026 Revenue Outlook, Aims for Profitability Amid Restructuring Drive

Geron Corporation (GERN) is a commercial-stage biopharmaceutical company focused on developing and selling treatments for blood cancers. The company has announced its 2026 outlook, forecasting $220-240 million in RYTELO revenue and $230-240 million in operating expenses. Geron is prioritizing US commercialization, international expansion, and progress in its Phase 3 IMpactMF trial. The company has embarked on a restructuring drive to achieve profitability in the second half of 2026 by trimming its workforce by nearly a third, resulting in $18 million in restructuring charges.